News

The Company’s Phase 3 protocol provides for a 25-week study with 300 HIV patients, which could start as early as 30 days after submission. The Company believes that

Results showed HUMIRA significantly lowered their risk of uncontrolled uveitis or vision loss. The results were presented at the Association for Research in Vision and Ophthalmology (ARVO) 2015

PKAN is believed to affect about one to three persons per million worldwide and there are currently no approved treatment available. The company has started the screening of

AATD is a rare genetic disorder that can severely damage the liver and lungs of affected individuals. The trial will start dose escalation in healthy volunteers (Part A)

The randomized, double-blinded, placebo-controlled trial will be conducted at sites in the US, Canada and Europe. The trial is designed to evaluate MM-141 in combination with nab-paclitaxel and

Ora is a US-based global, full-service ophthalmic clinical research and product development company. As part of the deal, Ora will lead the clinical development of PRT2671, and the

The therapeutic potential will be unlocked by combining ArQule’s chemistry and drug development expertise with Beryllium’s discovery platforms, which integrate structure-guided drug discovery, biophysics and cell biology. The

The Irish firm paid $101 per share to acquire Auspex’s portfolio of new medicines for people who live with movement disorders. Auspex’s lead product candidate SD-809 (deutetrabenazine) is

Around 5,000 individuals with systemic lupus erythematosus (lupus) will be enrolled in the trial to help better understand the genetics of lupus. Also involved in this collaboration is